Journal of cancer policyHumansNeoplasmsAntineoplastic AgentsClinical Trials as TopicResearch Design
Overall survival as a safety guardrail in cancer drug trials.
Rashidul Alam Mahumud
Published: 202510.1016/j.jcpo.2025.100666
Abstract
Surrogate endpoints have accelerated access to oncology drugs but often leave uncertainty about net patient benefit. We propose a pragmatic framework that recentres overall survival (OS) as both the definitive patient-centred efficacy endpoint and a…
Preview only. Read the full abstract at the source